246 related articles for article (PubMed ID: 36902214)
1. Acral Melanoma Is Infiltrated with cDC1s and Functional Exhausted CD8 T Cells Similar to the Cutaneous Melanoma of Sun-Exposed Skin.
De Leon-Rodríguez SG; Aguilar-Flores C; Gajón JA; Mantilla A; Gerson-Cwilich R; Martínez-Herrera JF; Rodríguez-Soto BE; Gutiérrez-Quiroz CT; Pérez-Koldenkova V; Muñoz-Cruz S; Bonifaz LC; Fuentes-Pananá EM
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902214
[TBL] [Abstract][Full Text] [Related]
2. Appraisal of clinicopathological prognosticators in advanced acral lentiginous melanoma with characterization of PD-L1 and CD8/CD4 immunoprofiles.
Chuang IC; Jang CS
Jpn J Clin Oncol; 2022 Sep; 52(9):975-981. PubMed ID: 35662346
[TBL] [Abstract][Full Text] [Related]
3. Tumoral PD-L1 expression in desmoplastic melanoma is associated with depth of invasion, tumor-infiltrating CD8 cytotoxic lymphocytes and the mixed cytomorphological variant.
Frydenlund N; Leone D; Yang S; Hoang MP; Deng A; Hernandez-Perez M; Singh R; Biswas A; Yaar R; Mahalingam M
Mod Pathol; 2017 Mar; 30(3):357-369. PubMed ID: 28084337
[TBL] [Abstract][Full Text] [Related]
4. Nodular primary cutaneous melanoma is associated with PD-L1 expression.
Giavina-Bianchi M; Giavina-Bianchi P; Sotto MN; Rodig S; Mihm M; Festa Neto C; Duncan LM; Kalil J
Eur J Dermatol; 2020 Aug; 30(4):352-357. PubMed ID: 32969795
[TBL] [Abstract][Full Text] [Related]
5. Difference in immunohistochemical findings among anti-PD-L1 antibodies and their relationships with CD4+ and CD8+ T cells in Japanese melanoma patients.
Yoneta D; Kato J; Kamiya T; Horimoto K; Sato S; Sawada M; Minowa T; Hida T; Sugita S; Uhara H
Int J Clin Oncol; 2022 Aug; 27(8):1364-1371. PubMed ID: 35650364
[TBL] [Abstract][Full Text] [Related]
6. Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells.
Inozume T; Hanada K; Wang QJ; Ahmadzadeh M; Wunderlich JR; Rosenberg SA; Yang JC
J Immunother; 2010; 33(9):956-64. PubMed ID: 20948441
[TBL] [Abstract][Full Text] [Related]
7. Melanoma subtypes demonstrate distinct PD-L1 expression profiles.
Kaunitz GJ; Cottrell TR; Lilo M; Muthappan V; Esandrio J; Berry S; Xu H; Ogurtsova A; Anders RA; Fischer AH; Kraft S; Gerstenblith MR; Thompson CL; Honda K; Cuda JD; Eberhart CG; Handa JT; Lipson EJ; Taube JM
Lab Invest; 2017 Sep; 97(9):1063-1071. PubMed ID: 28737763
[TBL] [Abstract][Full Text] [Related]
8. The helminth-derived peptide GK-1 induces an anti-tumoral CD8 T cell response associated with downregulation of the PD-1/PD-L1 pathway.
Rodríguez-Rodríguez N; Madera-Salcedo IK; Bugarin-Estrada E; Sánchez-Miranda E; Torres-García D; Cervantes-Torres J; Fragoso G; Rosetti F; Crispín JC; Sciutto E
Clin Immunol; 2020 Mar; 212():108240. PubMed ID: 31299381
[TBL] [Abstract][Full Text] [Related]
9. Multifunctionality of CD8
Manabe K; Yamasaki O; Nakagawa Y; Miyake T; Udono H; Morizane S
J Dermatol; 2021 Aug; 48(8):1186-1192. PubMed ID: 33890340
[TBL] [Abstract][Full Text] [Related]
10. Induction of Progenitor Exhausted Tissue-Resident Memory CD8
León-Letelier RA; Castro-Medina DI; Badillo-Godinez O; Tepale-Segura A; Huanosta-Murillo E; Aguilar-Flores C; De León-Rodríguez SG; Mantilla A; Fuentes-Pananá EM; López-Macías C; Bonifaz LC
Front Immunol; 2020; 11():583382. PubMed ID: 33240271
[TBL] [Abstract][Full Text] [Related]
11. Peritumoral Immune Infiltrate as a Prognostic Biomarker in Thin Melanoma.
Sabbatino F; Scognamiglio G; Liguori L; Marra A; Anniciello AM; Polcaro G; Dal Col J; Caputo A; Peluso AL; Botti G; Zeppa P; Ferrone S; Pepe S
Front Immunol; 2020; 11():561390. PubMed ID: 33117345
[TBL] [Abstract][Full Text] [Related]
12. Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases.
Kakavand H; Vilain RE; Wilmott JS; Burke H; Yearley JH; Thompson JF; Hersey P; Long GV; Scolyer RA
Mod Pathol; 2015 Dec; 28(12):1535-44. PubMed ID: 26403784
[TBL] [Abstract][Full Text] [Related]
13. The relationships between PD-L1 expression, CD8+ TILs and clinico-histomorphological parameters in malignant melanomas.
Škuciová V; Drahošová S; Výbohová D; Cígerová V; Adamkov M
Pathol Res Pract; 2020 Sep; 216(9):153071. PubMed ID: 32825944
[TBL] [Abstract][Full Text] [Related]
14. Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma.
Malvehy J; Samoylenko I; Schadendorf D; Gutzmer R; Grob JJ; Sacco JJ; Gorski KS; Anderson A; Pickett CA; Liu K; Gogas H
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33785610
[TBL] [Abstract][Full Text] [Related]
15. Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma.
Saito R; Sawada Y; Nakamura M
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669410
[TBL] [Abstract][Full Text] [Related]
16. Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites.
Kluger HM; Zito CR; Barr ML; Baine MK; Chiang VL; Sznol M; Rimm DL; Chen L; Jilaveanu LB
Clin Cancer Res; 2015 Jul; 21(13):3052-60. PubMed ID: 25788491
[TBL] [Abstract][Full Text] [Related]
17. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
18. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 expression in tumour-infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients.
Ren M; Dai B; Kong YY; Lv JJ; Cai X
Histopathology; 2018 Sep; 73(3):386-396. PubMed ID: 29637587
[TBL] [Abstract][Full Text] [Related]
20. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients.
Tang B; Yan X; Sheng X; Si L; Cui C; Kong Y; Mao L; Lian B; Bai X; Wang X; Li S; Zhou L; Yu J; Dai J; Wang K; Hu J; Dong L; Song H; Wu H; Feng H; Yao S; Chi Z; Guo J
J Hematol Oncol; 2019 Jan; 12(1):7. PubMed ID: 30642373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
